These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28158205)

  • 21. Identification and Evaluation of Olive Phenolics in the Context of Amine Oxidase Enzyme Inhibition and Depression: In Silico Modelling and In Vitro Validation.
    Karagiannis TC; Ververis K; Liang JJ; Pitsillou E; Liu S; Bresnehan SM; Xu V; Wijoyo SJ; Duan X; Ng K; Hung A; Goebel E; El-Osta A
    Molecules; 2024 May; 29(11):. PubMed ID: 38893322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.
    Schmidt DM; McCafferty DG
    Biochemistry; 2007 Apr; 46(14):4408-16. PubMed ID: 17367163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structurally designed trans-2-phenylcyclopropylamine derivatives potently inhibit histone demethylase LSD1/KDM1 .
    Mimasu S; Umezawa N; Sato S; Higuchi T; Umehara T; Yokoyama S
    Biochemistry; 2010 Aug; 49(30):6494-503. PubMed ID: 20568732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LSD1 in drug discovery: From biological function to clinical application.
    Liu HM; Zhou Y; Chen HX; Wu JW; Ji SK; Shen L; Wang SP; Liu HM; Liu Y; Dai XJ; Zheng YC
    Med Res Rev; 2024 Mar; 44(2):833-866. PubMed ID: 38014919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
    Zheng YC; Yu B; Jiang GZ; Feng XJ; He PX; Chu XY; Zhao W; Liu HM
    Curr Top Med Chem; 2016; 16(19):2179-88. PubMed ID: 26881714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-translational modifications of lysine-specific demethylase 1.
    Kim D; Nam HJ; Baek SH
    Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194968. PubMed ID: 37572976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human histone demethylase LSD1 reads the histone code.
    Forneris F; Binda C; Vanoni MA; Battaglioli E; Mattevi A
    J Biol Chem; 2005 Dec; 280(50):41360-5. PubMed ID: 16223729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug Design Concepts for LSD1-Selective Inhibitors.
    Ota Y; Suzuki T
    Chem Rec; 2018 Dec; 18(12):1782-1791. PubMed ID: 30277644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications.
    Lee MG; Wynder C; Schmidt DM; McCafferty DG; Shiekhattar R
    Chem Biol; 2006 Jun; 13(6):563-7. PubMed ID: 16793513
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone H3 peptide based LSD1-selective inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
    Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lysine-specific demethylase 1-selective inactivators: protein-targeted drug delivery mechanism.
    Ogasawara D; Itoh Y; Tsumoto H; Kakizawa T; Mino K; Fukuhara K; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N; Suzuki T
    Angew Chem Int Ed Engl; 2013 Aug; 52(33):8620-4. PubMed ID: 23824985
    [No Abstract]   [Full Text] [Related]  

  • 32. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TCPs: privileged scaffolds for identifying potent LSD1 inhibitors for cancer therapy.
    Zheng YC; Yu B; Chen ZS; Liu Y; Liu HM
    Epigenomics; 2016 May; 8(5):651-66. PubMed ID: 27102879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A selective phenelzine analogue inhibitor of histone demethylase LSD1.
    Prusevich P; Kalin JH; Ming SA; Basso M; Givens J; Li X; Hu J; Taylor MS; Cieniewicz AM; Hsiao PY; Huang R; Roberson H; Adejola N; Avery LB; Casero RA; Taverna SD; Qian J; Tackett AJ; Ratan RR; McDonald OG; Feinberg AP; Cole PA
    ACS Chem Biol; 2014 Jun; 9(6):1284-93. PubMed ID: 24707965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversible Lysine Specific Demethylase 1 (LSD1) Inhibitors: A Promising Wrench to Impair LSD1.
    Dai XJ; Liu Y; Xue LP; Xiong XP; Zhou Y; Zheng YC; Liu HM
    J Med Chem; 2021 Mar; 64(5):2466-2488. PubMed ID: 33619958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and biological activity of 3-oxoamino-benzenesulfonamides as selective and reversible LSD1 inhibitors.
    Xi J; Xu S; Wu L; Ma T; Liu R; Liu YC; Deng D; Gu Y; Zhou J; Lan F; Zha X
    Bioorg Chem; 2017 Jun; 72():182-189. PubMed ID: 28460360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LSD1 demethylates histone and non-histone proteins.
    Nicholson TB; Chen T
    Epigenetics; 2009 Apr; 4(3):129-32. PubMed ID: 19395867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of novel dual inhibitors targeting lysine specific demethylase 1 (LSD1) and histone deacetylases (HDAC) for treatment of gastric cancer.
    Duan YC; Jin LF; Ren HM; Zhang SJ; Liu YJ; Xu YT; He ZH; Song Y; Yuan H; Chen SH; Guan YY
    Eur J Med Chem; 2021 Aug; 220():113453. PubMed ID: 33957387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
    Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
    Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Systematic Review of Histone Lysine-Specific Demethylase 1 and Its Inhibitors.
    Zheng YC; Ma J; Wang Z; Li J; Jiang B; Zhou W; Shi X; Wang X; Zhao W; Liu HM
    Med Res Rev; 2015 Sep; 35(5):1032-71. PubMed ID: 25990136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.